This page contains brief information about belinostat and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
|US Brand Name(s):||Beleodaq|
Belinostat is approved to treat:
- Peripheral T-cell lymphoma that has recurred (come back) or is refractory (does not respond to treatment).
Belinostat is also being studied in the treatment of other types of cancer.More About Belinostat
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.Clinical Trials Accepting Patients
Find Clinical Trials for Belinostat - Check for trials from NCI's list of cancer clinical trials now accepting patients.
Important: The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.